MSH2 and urinary bladder carcinoma: Based on the co-expression levels of circLIFR and MSH2 (Fig. S5B), we divided the clinical bladder cancer tissues into two groups, circLIFRlow/MSH2low group (patient #135 and patient #150) and circLIFRhigh/MSH2high group (patient #348 and patient #615) (Fig. S5C).